Skip to main content

Cookies

This site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to the Privacy Policy and Terms of Use. Please read our cookie policy for more information on the use of cookies on this website.

Top
  • COVID-19
    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
  • Products
    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers
Home

Utility Navigation

  • Life Sciences Customer Login
  • GENEWIZ
  • BioInventory Login
  • Portals Login
  • Portals
  • Careers

Main Navigation

  • COVID-19
    Vaccine Development
    Vaccine Development

    Accelerating global operations to manage and process samples critical to vaccine development.

    Azenta Life Sciences Virtual Booth
    Azenta Life Sciences Virtual Booth

    The exhibition experience to your desktop or mobile device

    • COVID-19 Resources
  • Solutions
    • By Market
      • Academic Research
      • Agriculture
      • Biobanking
      • Government
      • Pharma and Biotech
      • Research Foundations
    • By Application
      • Clinical Trial Sample Management
      • Discovery, Compound Management and Biologics
      • Molecular Diagnostic Solutions
      • Regenerative Medicine and Cell Therapy
      • Sample Preparation and Lab Services
      • Sample Transport and Cold-Chain Logistics
      • Vaccine Development
    • Geography
      • Asia-Pacific
      • Europe
      • North America
    Resources Center

    Learn about sample management best practices, gain advice from industry leaders, gain access to global regulatory and logistics guidelines and find simple support tools that can help you make better sample management decisions.

    Resources Center
  • Products
    Azenta Sample Pack and Catalog
    Sample Tube Pack Request

    Improve sample tracking, ensure sample integrity and drive process efficiency with Azenta Sample Storage Tubes. Explore the range, and select the best tube for your workflow.

    Low DNA Binding Microplates
    Low Binding Microplates

    Ultra low DNA binding microplates made from PP, fit for Next Generation Sequencing (NGS) and other sensitive applications with ultra-low DNA input. Off the shelf options. Custom solutions on request.

    • Azenta Life Sciences Virtual Booth
    • Automated Sample Storage Systems
      • Cold Storage (Ambient to -20°C)
      • Ultra Cold Storage (ULT -80°C)
      • Cryogenic Storage (-190°C)
    • Consumables & Instruments
      • Sample Tube Solutions
      • PCR & Microplate Solutions
      • Sample Cooling & Heating Labware
    • Informatics Platforms & LIMS/LIS
    • Integrations
    • Sterilization Services
    • Microplate Coding Services
  • Services
    Clinical Trial Management
    Clinical Trial Management

    Life science organizations must collect and manage large numbers of research samples to bring a new therapeutic or diagnostic to market. This is a complex process.

    Sample Preparation & Lab Analytical Services
    Genomics Services by GENEWIZ

    Comprehensive genomics services provide end to end solutions and best-in-class data quality from the trusted experts in genomics.

    • Genomics Services by GENEWIZ
    • Sample and Material Management Solutions
    • Sample and Material Storage
    • Clinical Trial Management
    • Drug Products Storage and Distribution
    • Sample Sourcing
    • Sample Prep and Lab Services
    • Lab Moving and Biological Transport
    • Business Continuity and Risk Mitigation
  • Support
    disaster recovery
    How Safe Are Your Samples?

    Plastic storage tubes are used in laboratories worldwide to store biological and chemical samples.

    Product Support Plans
    Product Support Plans

    Azenta  Life Sciences' world class service team is committed to ensuring you meet your business objectives by providing a flexible portfolio of service products designed to optimize up-time and productivity.

    • Technical Support
    • Product Support Plans
    • Product Updates
    • Sample Tube Pack Request
    • Plate & Seal Sample Request
  • Resources
  • Blog
  • About Us
    Putting a Sample Kit in an envelope
    Quality Assurance Certifications

    Azenta Life Sciences has established, documented, implemented and currently maintains a quality management system that fulfills the needs of customers.

    About Azenta Life Sciences
    About Azenta Life Sciences

    We are Azenta Life Sciences. We provide unrivaled sample exploration and management solutions to help our customers accelerate discovery, development and delivery.

    • Events
    • About Azenta Life Sciences
    • Management Team
    • Board of Directors
    • Global Locations
    • Investor Relations
    • News
    • Careers
    • Quality
    • Certifications
  • Contact Us

Blog

You are here

  • Home
  • Blog
  • Lentivirus Production for Gene Delivery

Lentivirus Production for Gene Delivery

June 7, 2022

Lentivirus Production for Gene Delivery

 

With the emergence of cell and gene therapy and other gene editing technologies, interest in efficient and effective gene delivery systems has surged in recent years. Commonly used systems include adeno-associated viruses (AAV) and lentiviruses. While both are effective transfer vehicles, there are key differences in how they infect cells and deliver their genetic payload. Most notably, lentiviruses have broader host-cell tropism than AAVs and offer stable integration into the host cell, whereas AAV tropism is narrower and only offers transient or episomal expression. Consequently, lentiviruses are the most utilize viral delivery system in both research and gene therapy applications. Here, we discuss how lentiviruses have been engineered to deliver transgenes safely and how researchers today generate lentiviral preparations.

 

Cellular Transduction with Lentivirus

Lentiviruses are enveloped retroviruses containing a single-stranded RNA genome. They are derived from the Retroviridae family, with some of the best-studied lentiviruses stemming from HIV and FIV. They utilize host cell machinery to enter target cells and manufacture protein and RNA components that self-assemble into infectious particles. Lentiviruses can infect both dividing and non-dividing cells and stably integrate their cargo into the host cell’s genome.

Infection begins when the glycoprotein envelope of the virus binds to the cell. Upon entry into the host cell, uncoating occurs followed by reverse transcription, mediated by a viral reverse transcriptase. The resulting linear double-stranded DNA is imported into the nucleus and is inserted into the host cell’s genome. The integrated viral genome, or provirus, undergoes transcription and translation to produce viral proteins, including structural proteins, enzymes, and gene regulators. The proteins and RNA copies assemble, bud, and mature, producing new viral particles (Figure 1).

 

Lentivirus Life Cycle

 

Figure 1: Lentivirus Life Cycle

 

Lentivirus Production Overview

Using lentiviruses as gene delivery vehicles requires a series of steps to introduce the gene of interest (GOI) into a modified version of the viral genome and package it into a functional viral particle (Figure 2). First, the sequence of the GOI is designed and optimized for expression in the host organism. Consider the following recommendations when designing the construct.

  • The transgene construct should be <9 kb for efficient lentiviral packaging
  • Avoid internal poly A signals; they terminate transcription of GOI and other required genes
  • Avoid toxic gene loads or unusual secondary structures
  • Include a Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element (WPRE) sequence to enhance expression and facilitate functional titering (see ‘Titering Option’ section below)

The DNA is then synthesized and cloned into a lentiviral vector containing the necessary elements for genomic integration—such as long terminal repeat (LTR) regions—and expression (e.g., promoter). The plasmid DNA is amplified and transfected into a packaging cell line, such as HEK293T, which produces viral particles. Lastly, the concentration of viruses, or titer, is measured prior to use.

 

Typical workflow for lentiviral packaging

Figure 2. Typical workflow for lentiviral packaging

 

Current Lentiviral Vectors

As lentiviruses have grown in popularity for therapeutic applications, research and development has improved their efficacy and safety. Early lentiviral vectors (lentivectors) had the potential to generate replication-competent viruses, posing an infection risk to those working with them. Third generation vectors systems have segregated the integral pieces for gene transfer, packaging, and replication into separate plasmids that allow viral replication to proceed only when all necessary components are co-transfected into a cell line (see Figure 3). Additionally, the 3’ LTR of these vectors has been truncated to remove the tat gene, responsible for export of the virus from the host cell. This alteration makes these viruses replication incompetent and improves overall safety of the system. Fourth generation vectors have taken this a step further by also separating the gag (structural gene) and pol (reverse transcriptase/integrase) onto separate plasmids.

 

Lentivirus Packaging of 3rd Generation Replication-Incompetent Virus

 

Figure 3. Lentivirus Packaging of 3rd Generation Replication-Incompetent Virus

 

Lentiviral transfer vectors can drive transgene expression through different promoters, depending on the cell type that’s infected (see Table 1). Additionally, most vectors contain markers such as fluorescent proteins and/or antibiotic resistance genes for selection (e.g., puromycin). Lentiviral vectors offer a wide range of options for the co-expression of two transgenes, such as dual promoters or an internal ribosomal entry site (IRES). The IRES element, located between the two transgenes in the bicistronic vector, recruits ribosomes to initiate translation in a cap-independent manner. Other lentiviral vectors utilize the 2A ribosome skipping mechanism to generate multiple proteins from one transcript. The coding sequence for the 2A peptide, composed of 18 to 22 amino acids, is inserted between the two transgenes in the lentiviral construct. When the transcript is translated, the 2A peptide prevents normal peptide bond formation at its C terminus, cleaving the protein into two separate peptides.

 

PROMOTER EXPRESSION LEVEL APPLICATION
CMV High Commonly used in most cell lines (HeLa, HEK293, HT1080, etc.)
MSCV High Hematopoietic and stem cells
EF1α Medium Most cell types including primary cells and stem cells
PGK Medium Most cell types including primary cells and stem cells
UbC Low Most cell types including primary cells and stem cells

Table 1. Lentivirus Transfer Vector Promoters and Markers

 

Titering Options for Lentiviral Preps

Measuring the titer of lentiviral preparations can be performed by two approaches: physical and functional. Physical titering measures the number of viral particles present in the sample, whereas functional titering measures the number of viral particles that can infect cells (Figure 4). Physical titering is typically performed via enzyme-linked immunoassay (ELISA) of the viral protein P24 and is reported in transduction units (TUs) per mL. This method, while fast, is not the most accurate because the functionality of the virus is not considered. Physical titers can be 10- to 1000-fold higher than the functional virus in a sample, which could impact the reproducibility of results between preps. With functional titering, a control cell line (often HT1080 cells) is transduced with the viral sample. The amount of infectious viral particles is determined by qPCR of the WPRE element, reported as infectious units (IFU) per mL.

 

Physical versus Functional Titering of Lentivirus

 

Figure 4. Physical versus Functional Titering of Lentivirus

 

Key Takeaways

  • Lentiviruses are effective gene delivery systems, targeting a wide range of host cells and enabling stable expression of transgenes
  • The latest generation of lentiviral vectors offer a high degree of biosafety with customizable promoters based on the research need
  • Functional titering ensures the most accurate measurement of active viruses in a lentiviral preparation, improving downstream applications

Ready to use lentivirus as a gene delivery vector for your research? Learn how lentiviral packaging solutions can streamline the whole process.

 

Find Your Solution

 

References

Crespo-Barreda, M.M. Encabo-Berzosa, R. González-Pastor, P. Ortíz-Teba, M. Iglesias, J.L. Serrano, P. Martin-Duque. Chapter 11 - Viral and Nonviral Vectors for In Vivo and Ex Vivo Gene Therapies, Editor(s): Jeffrey Laurence,Translating Regenerative Medicine to the Clinic, Academic Press, 2016, Pages 155-177, ISBN 9780128005484.
Dong, W.; Kantor, B. Lentiviral Vectors for Delivery of Gene-Editing Systems Based on CRISPR/Cas: Current State and Perspectives. Viruses 2021, 13, 1288. https://doi.org/10.3390/v13071288
Gándara, Carolina, Valerie Affleck, and Elizabeth Ann Stoll. "Manufacture of third-generation lentivirus for preclinical use, with process development considerations for translation to good manufacturing practice." Human gene therapy methods 29.1 (2018): 1-15
Global Lentiviral Vector Market – Industry Trends and Forecast to 2028. Data Bridge Market Research, June, 2021. https://www.databridgemarketresearch.com/reports/global-lentiviral-vector-market
Milone, Michael C., and Una O’Doherty. "Clinical use of lentiviral vectors." Leukemia 32.7 (2018): 1529-1541.
Naso, Michael F, et al. “Adeno-Associated Virus (AAV) as a Vector for Gene Therapy.” BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy, Springer International Publishing, Aug. 2017.

  • Genomics
  • Cell & Gene Therapy
  • Gene Synthesis
  • Vaccine
Home
Facebook twitter youtube linkedin
Copyright © 2023 Azenta US, Inc.

Footer menu

  • Privacy Policy
  • Cookie Policy
  • Terms and Conditions
  • Terms of Use
  • Careers
  • Subscribe